Skip to main content
TipRanks
Go Ultimate75% OFF

Captor Therapeutics SA (60Q) AI Stock Analysis

1 Followers
DE:60Q

Captor Therapeutics SA

(Stuttgart:60Q)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Proprietary Technology PlatformCaptor Therapeutics' TPD platform offers a unique approach to drug development, potentially providing a competitive edge in creating novel therapies for oncology and autoimmune diseases.
Negative Factors
Declining RevenueA significant decline in revenue growth poses a challenge to financial sustainability, impacting the company's ability to fund operations and invest in future growth opportunities.

Captor Therapeutics SA (60Q) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%DE:60Q-5.19%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 74.81M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-6.7
Beta (1Y)
0.41
Revenue Growth
-81.85%
EPS Growth
-3.69%
Country
Germany
Employees
82
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Captor Therapeutics SA Business Overview & Revenue Model

Company Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes man...

Captor Therapeutics SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:60Q against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PL:RVUPL:RVU37UnderperformPLN 390.27M-5.61-139.66%―-10.07%47.47%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:60QPL:MQRPL:RVUPL:MOCPL:NNGPL:PTGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:60Q and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:60QCaptor Therapeutics SA11.520.221.95%
PL:MQRPure Biologics SA1.30-3.04-70.05%
PL:RVURyvu Therapeutics SA16.18-8.32-33.96%
PL:MOCOncoArendi Therapeutics SA5.20-0.81-13.48%
PL:NNGNanoGroup SA2.03-1.09-34.94%
PL:PTGPolTREG Spolka Akcyjna17.90-8.10-31.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.